Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of BMS-986416 alone and with nivolumab in selected advanced solid tumors
jRCT2031210475Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jan 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
01
Overview
Phase 1, open-label trial of AVID200 and nivolumab in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC), transitional cell carcinoma (TCC) and 4 more (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Incidence of adverse events, Incidence of serious adverse events and 4 more. Started Jan 2022; status: completed.
02
Drugs
AVID200nivolumab
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)transitional cell carcinoma (TCC)head and neck squamous cell carcinoma (HNSCC)hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on jRCT2031210475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210475.